Abstract Objective To study the effect of vaccination on the short-term risk of immunoglobulin A vasculitis (IgAV) in children. Methods A retrospective analysis was conducted on the general data and the vaccination history within one year prior to onset in children with IgAV hospitalized in the Children's Hospital Affiliated to Zhengzhou University from November 2021 to January 2023. Vaccine exposure rates in the risk period (3 months prior to IgAV onset) and the control period were compared by autocontrol-case crossover analysis, and the odds ratio and 95% confidence interval (95%CI) were calculated. A sensitivity analysis for the one-month and two-month risk periods was conducted. Results A total of 193 children with IgAV were included, with a median age of 7.0 years. Among the 193 children, 36 (18.7%) received at least one dose of the vaccine within 1 year prior to IgAV onset, and 14 (7.3%) received at least one dose of the vaccine during the 3-month risk period. Compared to the unvaccinated IgAV group, the vaccinated IgAV group had a significantly younger age of onset (P<0.05). There were no significant differences in the proportions of children with gastrointestinal involvement, renal involvement, and joint involvement between the two groups (P>0.05). The odds ratio for developing IgAV after receiving any type of vaccine within 3 months prior to IgAV onset was 2.08 (95%CI: 0.82-5.27, P>0.05). Further sensitivity analysis for the 1-month and 2-month risk periods demonstrated that the odds ratios for developing IgAV after receiving any type of vaccine were 2.74 (95%CI: 0.72-10.48, P>0.05) and 2.72 (95%CI: 0.95-7.77, P>0.05), respectively. Conclusions Vaccination dose not increase the risk of IgAV, nor does it exacerbate clinical symptoms in children with IgAV.
CAO Feng,XU Long-Wei,ZHANG Ying-Hui. Association between vaccination and the risk of immunoglobulin A vasculitis in children[J]. CJCP, 2023, 25(11): 1137-1142.
CAO Feng,XU Long-Wei,ZHANG Ying-Hui. Association between vaccination and the risk of immunoglobulin A vasculitis in children[J]. CJCP, 2023, 25(11): 1137-1142.
Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis: the SHARE initiative[J]. Rheumatology (Oxford), 2019, 58(9): 1607-1616. PMID: 30879080. DOI: 10.1093/rheumatology/kez041.
Shu M, Liu Q, Wang J, et al. Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008[J]. Vaccine, 2011, 29(18): 3507-3510. PMID: 19909830. DOI: 10.1016/j.vaccine.2009.10.106.
Watanabe T. Henoch-Sch?nlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1)[J]. Pediatr Nephrol, 2011, 26(5): 795-798. PMID: 21120537. DOI: 10.1007/s00467-010-1722-8.
Piram M, Gonzalez Chiappe S, Madhi F, et al. Vaccination and risk of childhood IgA vasculitis[J]. Pediatrics, 2018, 142(5): e20180841. PMID: 30377240. DOI: 10.1542/peds.2018-0841.
Xu Y, Wang JJ, Liu FF, et al. Predisposing factors of childhood Henoch-Sch?nlein purpura in Anhui province, China[J]. J Investig Med, 2019, 67(4): 771-778. PMID: 30530785. DOI: 10.1136/jim-2018-000906.
Jariwala S, Vernon N, Shliozberg J. Henoch-Sch?nlein purpura after hepatitis A vaccination[J]. Ann Allergy Asthma Immunol, 2011, 107(2): 180-181. PMID: 21802028. DOI: 10.1016/j.anai.2011.05.006.
Sexton K, McNicholas A, Galloway Y, et al. Henoch-Sch?nlein purpura and meningococcal B vaccination[J]. Arch Dis Child, 2009, 94(3): 224-226. PMID: 18650242. DOI: 10.1136/adc.2007.125195.
Anderson EJ, Daugherty MA, Pickering LK, et al. Protecting the community through child vaccination[J]. Clin Infect Dis, 2018, 67(3): 464-471. PMID: 29471452. DOI: 10.1093/cid/ciy142.
Hernandez Quiroz E, Kauffman CL, Kupiec-Banasikowska A. Erythema multiforme following hepatitis a and pneumococcal vaccinations[J]. Yale J Biol Med, 2022, 95(2): 213-215. PMID: 35782476. PMCID: PMC9235263.
Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group[J]. N Engl J Med, 2001, 344(5): 319-326. PMID: 11172162. DOI: 10.1056/NEJM200102013440501.
Ali A, Waris A, Khan MA, et al. Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections[J]. Life Sci, 2023, 314: 121332. PMID: 36584914. DOI: 10.1016/j.lfs.2022.121332.